Yuhan Corporation

Yuhan and Cyrus Partner to Develop Innovative Small-Molecule Anti-Cancer Drug

by
Yuhan and Cyrus Partner to Develop Innovative Small-Molecule Anti-Cancer Drug

Expect synergy between Cyrus’ anti-cancer drug discovery capabilities and Yuhan’s translational clinical research capabilities Looking forward to quickly discovering the second Lexraza with global competitiveness From left, Kim Byung-moon, CEO of Cyrus Therapeutics, and Cho Wook-je, CEO of Yuhan Corporation (Photo Credit=Yuhan Corporation) [바이오타임즈] Yuhan Corp. (CEO Wook-Je Cho) announced that it had signed a … Read more

Yuhan Corporation Sustainability Management Report and New Drug Development Activities

by
Yuhan Corporation Sustainability Management Report and New Drug Development Activities

Yuhan Corporation publishes sustainability management report… Details of new drug development and R&D activities Yuhan Corporation Sustainability Report 2022-2023 Cover (Data = Yuhan Corporation) [이데일리 나은경 기자] Yuhan Corporation (000100) published a sustainability report on the 28th to transparently disclose its environmental, social, and governance (ESG) management performance and future plans for the past year … Read more

Yuhan Corporation’s Lexraza Early Access Program: Strategies for First-Line Treatment Market and Patient Choice

by
Yuhan Corporation’s Lexraza Early Access Program: Strategies for First-Line Treatment Market and Patient Choice

choice for patients? Strategies for occupying the first-line treatment market? CEO Cho Wook-je “There is no purpose to attract patients… Proceed EAP with confidence” Professor of Oncology “Not for companies or hospitals, only for patients” Cho Wook-je, CEO of Yuhan Corporation ⓒUihyup Shinmun Is Yuhan’s free supply of Lexraza a choice for patients? Is it … Read more

Yuhan Corporation Implements Free Supply Program for Rexraza in Non-Small Cell Lung Cancer Treatment

by
Yuhan Corporation Implements Free Supply Program for Rexraza in Non-Small Cell Lung Cancer Treatment

[딜사이트 민승기 기자] Yuhan Corporation will start a free supply program (EAP) for non-small cell lung cancer treatment ‘Rexraza (ingredient name: Lazertinib)’ in earnest. Unlike normal EAP, this EAP is conducted in a way that does not limit the number of medical institutions and patients. In some hospitals, the relevant review process is nearing the … Read more

Yuhan Corporation Receives Approval for Rexraza as First-Line Treatment for EGFR Mutation-Positive Non-Small Cell Lung Cancer

by
Yuhan Corporation Receives Approval for Rexraza as First-Line Treatment for EGFR Mutation-Positive Non-Small Cell Lung Cancer

[이데일리 신민준 기자] Yuhan Corporation (000100) announced that it had received item approval from the Ministry of Food and Drug Safety for Lexraza (ingredient name: Lazertinib mesylate monohydrate) as a first-line treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) 30 the day said Rexraza (tablets) 80mg. (Photo = Yuhan Corporation) … Read more

Yuhan Corporation Reshuffles Executive Personnel in R&D Reorganization

by

On May 30, executive personnel were reshuffled. Yuhan Corp. has appointed Kim Yeol-hong, head of the R&D headquarters (president), as the general manager of R&D. On May 30, Yuhan Corporation (CEO Wook-Je Cho) reorganized some organizations and reshuffled executives to improve the efficiency of the R&D organization and secure growth engines. The central research institute … Read more